---
title: RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin
nct_id: NCT00485342
overall_status: UNKNOWN
phase: PHASE3
sponsor: Hospices Civils de Lyon
study_type: INTERVENTIONAL
primary_condition: Chronic Hepatitis C
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00485342.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00485342"
ct_last_update_post_date: 2012-01-09
last_seen_at: "2026-05-12T07:03:55.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# RIBAJUSTE Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin

**Official Title:** Multicentric, Controlled and Randomised Open Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin Using Pharmacologic Measures of Ribavirin Exposition During Combination Peginterferon Alfa-2 and Ribavirin Treatment in Naive Patients With Chronic Hepatitis C of Genotype 1 on a First Combination Therapy

**NCT ID:** [NCT00485342](https://clinicaltrials.gov/study/NCT00485342)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 236
- **Lead Sponsor:** Hospices Civils de Lyon
- **Conditions:** Chronic Hepatitis C
- **Start Date:** 2006-04
- **Completion Date:** 2013-03
- **CT.gov Last Update:** 2012-01-09

## Brief Summary

The aim of this study is to compare two therapeutical strategies concerning the combination therapy (peginterferon alfa-2a and ribavirin) in naïve patients with chronic hepatitis C of genotype 1. "Reference" strategy corresponding to standards of care recommended by the French consensus conference versus "Test" strategy corresponding to adaptation strategy of ribavirin dose during the first week according to AUC (area under the curve) of ribavirin plasmatic concentration after the first intake (Day 0) of 600 mg

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 65 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* 65 years \>Age \>= 18 years
* Chronic hepatitis C documented by PCR performed within 3 months and at liver biopsy within 18 months or with serum markers of fibrosis performed within 3 months before inclusion or FibroScan performed
* Naive patients for who the physician decided to initiate a combination treatment of chronic hepatitis C with pegylated interferon alfa-2a plus ribavirine
* Genotype VHC-1
* Compensated liver disease (Child-Pugh \<=6)
* Negative HBsAg test and HIV-RNA test
* Negative pregnancy test at baseline in women in age of procreation and efficient contraception all along the treatment period, and up to 7 months after discontinuation for women and men
* Signed consent form
* Patient with a social cover

Exclusion Criteria:

* Non HCV liver disease
* Non-1 HCV genotype
* Organ transplant whatever the organ
* Clinical or radiological evidence of liver carcinoma
* Severe psychiatric disorder
* Non compensated thyroid dysfunction
* Woman pregnant or breast-feeding
* Recent history of epilepsy (less than 6 months)
* Absolute contraindications to one of the drug of combination therapy
* Biological abnormalities at pre-treatment check-up, such as:

Neutropenia (\<1500/mm³); Haemoglobinemia (\<13 g/dL for men et \<12 g/dL for women); Thrombopenia (\<90 000/mm³);

* Kidney failure (creatinine clearance\>70 ml/min)
* Hypersensitivity to epoetin or one of its excipients
* Treatment by epoetin within 2 months prior inclusion
* Chronic cardiac failure (grade III or IV - NYHA classification)
* High blood pressure unwell-controlled (SBP \> 180 mmHg during inclusion in spite of hypertension treatment)
* Previous history or risk of venous thrombosis
* Major surgery within the previous 3 months
```

## Arms

- **standard dose** (NO_INTERVENTION) — the "reference" strategy : Peg-interferon alpha 2a (180 µg/week) and ribavine (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg)
- **adjusted dose** (EXPERIMENTAL) — individual dose adjustment of ribavirin dose at D7, based on ribavirin abbreviated AUC-0-4H , estimated itself by two independent methods: multiple linear regression and bayesien estimation based on three ribavirin concentration measurements obtained at 0.5H, 1H, 2H after the first intake of 600 mg at D0.

## Interventions

- **Peg-interferon alpha 2a and ribavin** (DRUG) — Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight \< 75 kg and 1200 mg/day if weight ≥ 75 kg).

Duration of treatment : 48 weeks Duration of study for patients : 72 weeks
- **ribavirin with adaptation dose** (DRUG) — Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.

The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks

## Primary Outcomes

- **Inter-group comparison of sustained virological response rates as defined by the proportion of subjects with a negative PCR HCV-RNA test at Week 72** _(time frame: 72 weeks)_

## Secondary Outcomes

- **Efficacy endpoints** _(time frame: 72 weeks)_
- **safety endpoints** _(time frame: 72 weeks)_
- **Economic endpoints** _(time frame: 72 weeks)_

## Locations (1)

- Marianne Maynard, Lyon, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.marianne maynard|lyon||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00485342.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00485342*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*